There is a large bulk of evidence that using low glycemic index (GI) foods has a
very significant impact on the amelioration of metabolic disturbances observed in
diabetic and/or hyperlipidemic patients and in subjects affected by the metabolic
syndrome. Studies bringing convincing evidence against this concept are very rare
if any. Improvement is observed not only in postprandial blood glucose and insulin
variations but also in circulating plasma lipid levels and the morphology and function
of adipocytes. Using the concept of low GI foods in diet counseling of diabetic patients
is not exclusive of other measures to improve postprandial and overall blood glucose
control. On the contrary, the use of low GI foods should be considered as one of other
means and tools available to improve diabetes control (such as other dietary modifications,
use of specific and nonspecific drug therapy altering postprandial blood glucose).
Among these therapies, the most promising ones are α-glucosidase inhibitors,
glynides, rapid insulin analogues and in the near future the GLP1 analogue. Again, all
these classes of drugs could be associated with one another in order to obtain a postprandial
delta excursion target of not below 20 and not above 40-50 mg/dl blood
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.